Valsartan Sacubitril: Has our PARADIGM shifted?

Patients with heart failure with preserved ejection fraction (HFpEF) suffer from poor survival, high hospitalisations rate and long-term mortality. HFpEF patients are often overlooked as compared to the more well-known HFrEF where the famous “fantastic four” are now well-known as disease-modifying therapies. The plethora of evidence-based studies have time and again proven their value in the modification of the untoward outcomes in the latter.

A recent ARNI trial has shown potential benefits of valsartan sacubitril on patients with HFpEF. Does that change the paradigm of how HFpEF should now be treated? Let us explore how we could apply the trial findings into our real-world clinical practice.

• To evaluate and understand which patients should and should not be prescribed valsartan sacubitril and which patients groups might benefit most;
• To determine how valsartan sacubitril should be administered and what dosage adjustments and drug interactions need to be noted;
• To analyse special and regional issues that impact the use of this drug;
• To apply evidence-based recommendations to two real-world cases.

• Cardiovascular team members – doctors, nurses, pharmacists
• Family physicians
• Internists
• Cardiovascular pharmacotherapy researchers

Led by moderators Janice Wong (Malaysia) and Doreen Tan (Singapore), it includes a speaker presentation from Giuseppe Rosano (UK) and a discussion from panelists Richard Henry Tiongco (Philippines) and Rungroj Krittayphong (Thailand) that will examine the potential use of this agent in HFpEF population, through consideration of real-world examples, live discussions, and audience Q&A.